IMPACT OF NADPH OXIDASE FUNCTIONAL POLYMORPHISMS IN ACUTE MYELOID LEUKAEMIA INDUCTION CHEMOTHERAPY
PKP-019
PHARMACOLOGICAL INTERACTIONS REGISTERED WITH THE USE OF NEW DIRECT ACTING ANTIVIRAL AGENTS FOR TREATMENT OF HEPATITIS C VIRUS
PKP-014
INFLUENCE OF THE GENETIC POLYMORPHISMS ON THE RESPONSE TO CLOPIDOGREL IN PERIPHERAL ARTERY DISEASE PATIENTS FOLLOWING PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY
PKP-013
LEVETIRACETAM THERAPEUTIC MONITORING IN PATIENTS WITH EPILEPSY: EFFECT OF CONCOMITANT ANTIEPILEPTIC DRUGS
PKP-012
BODY SURFACE AREA, CIGARRETE SMOKING AND INFLIXIMAB RESPONSE IN PATIENTS WITH PSORIASI
PKP-011
AMIKACIN ACCUMULATION IN PATIENTS WITH NORMAL RENAL FUNCTION AND ONCE DAILY DOSING BASED ON ACCEPTED TROUGH TARGETS
PKP-010
IMPACT OF THE RS1143634 POLYMORPHISM OF INTERLEUKIN 1b ON INFLIXIMAB EXPOSURE IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS
PKP-009
EVALUATION OF A POPULATION PHARMACOKINETIC MODEL OF INFLIXIMAB IN RHEUMATOID ARTHRITIS FOR PREDICTION OF INDIVIDUAL DOSAGE REQUIREMENTS
PKP-007
PHARMACIST LED RAPID POINT OF CARE CYTOCHROME P 2C19 GENOTYPING FOR INDIVIDUALISATION OF ANTIPLATELET THERAPY
PKP-006
ABCB1 AND OPRM1 POLYMORPHISMS ALTER MATERNAL EFFICACY AND NEONATAL SAFETY OF REMIFENATNIL IN WOMEN UNDERGOING CAESAREAN SECTION
PKP-005
EFFECT OF GENETIC POLYMORPHISM OF AZATHIOPRINE METABOLISING ENZYMES ON RESPONSE TO RHEUMATOID ARTHRITIS TREATMENT
PKP-004
ASSESSMENT OF COMPLIANCE OF PHARMACOKINETIC MONITORING REQUEST CRITERIA IN VANCOMYCIN AND AMINOGLYCOSIDE PRESCRIPTIONS
PKP-003
EVALUATING PRESCRIPTIVE APPROPRIATENESS AND PHARMACOLOGICAL INTERACTION IN ELDERLY PATIENTS UNDERGOING POLYTHERAPY IN NURSING HOMES
PKP-002
SECURITY PROFILE OF PATIENTS TREATED WITH PHENYTOIN IN A HOSPITAL
PKP-001
INFLUENCE OF GENDER AND BODY SIZE ON 5- FLUOROURACIL PHARMACOKINETIC
